Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2

I. Abbate, M. Guida, M. D. Musci, A. Casamassima, A. Latorre, L. Addabbo, C. D. Dragone, M. Cattedra, M. Correale, M. De Lena

Research output: Contribution to journalArticle

Abstract

Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.

Original languageEnglish
Pages (from-to)603-606
Number of pages4
JournalInternational Journal of Oncology
Volume3
Issue number4
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2'. Together they form a unique fingerprint.

  • Cite this

    Abbate, I., Guida, M., Musci, M. D., Casamassima, A., Latorre, A., Addabbo, L., Dragone, C. D., Cattedra, M., Correale, M., & De Lena, M. (1993). Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2. International Journal of Oncology, 3(4), 603-606.